MSD Korea will supply the hepatitis C treatment Zepatier in Korean market

Published: 2017-03-20 15:29:45

Updated: 2017-03-20 15:29:45

MSD Korea(CEO Avi BenShoshan) announced the launch of its own chronic hepatitis C treatment Zepatier™ (generic name: elbasvir/grazoprevir) on the 16^th.

With the launch, Zepatier, a drug for the treatment of genotype 1a and 1b patients with or without ribavirin(RBV), now can be used as the 12-week single therapy for patients having no treatment history and the 16-week RBV combination therapy fo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.